CYP2E1 and ovarian carcinoma: Identification of stronger associations between acrylamide and ovarian cancer in genetically susceptible individuals (e.g., of a certain CYP2E1 genotype) increases confidence that the observed association between acrylamide intake and ovarian cancer is not due to chance or bias.